Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (NCT06449222)
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Who can join: Review the eligibility criteria below.
Location: Beverly Hills Cancer Center — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- Beverly Hills Cancer Center — Beverly Hills, California
- Valkyrie Clinical Trials — Los Angeles, California
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center — Palo Alto, California
- Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
- Rocky Mountain Cancer Centers (RMCC) — Denver, Colorado
- Yale University - Yale Cancer Center — New Haven, Connecticut
- Carle Foundation Hospital d/b/a Carle Cancer Center — Urbana, Illinois
- HealthPartners Regions Specialty Clinics — Saint Louis Park, Minnesota
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey) — New Brunswick, New Jersey
- Stony Brook University Hospital — Stony Brook, New York
- The West Clinic, P.C. d/b/a West Cancer Center — Germantown, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- Bon Secours St. Francis Medical Center — Midlothian, Virginia
- Peninsula Oncology Centre — Frankston,
- Peter MacCallum Cancer Centre — Melbourne,
- Baskent Universitesi Tip Fakultesi Adana Hastanesi — Adana,
- Medical Park Seyhan Hospital — Adana,
- Sakarya University - Faculty of Medicine — Adapazarı,
- Hacettepe Universitesi Kanser Enstitusu — Ankara,
- Sbu Dr.A.Y. Ankara Onkoloji SUAM — Ankara,
- Memorial Ankara Hospital — Ankara,
- Koc Universitesi Hastanesi (Koc University Hospital) — Istanbul,
- Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi — Istanbul,
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi — Istanbul,
- Yeditepe University Hospital — Istanbul,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced Breast Cancer
Explore by condition: All Locally Advanced Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.